<DOC>
	<DOCNO>NCT00458146</DOCNO>
	<brief_summary>The purpose study determine whether MM-093 safe effective treatment RA .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Efficacy Safety 60mg MM-093 Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description>To evaluate safety tolerability 60 mg MM-093 patient active RA despite MTX background therapy .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Meet American College Rheumatology ( ACR ) criterion RA . Have active RA consist &gt; equal 6 tender joint &gt; equal 6 swollen joint one following : CRP ESR level ULN Have ACR functional class IIII . Have RA least 6 month . Had disease onset &gt; 16 year age . Aged 18 80 year . Currently treat stable , well tolerated weekly dose MTX 1025 mg least 6 consecutive prior screen visit . Currently treat folic/folinic acid conjunction MTX treatment . ( Note : Patients may begin folic/folinic acid treatment screen visit , must remain stable dose two week undergoing Day 1 assessment . ) Willing remain constant , weekly dose MTX folic/folinic acid duration study . Understand , sign , date write , voluntary inform consent form screen visit prior protocol specific procedure perform . Be able willing comply study visit procedure per protocol . Women childbearing potential must use medically acceptable mean birth control effective manner agree continue use study 4 week last dose study drug . Women complete surgical hysterectomy postmenopausal ( absence menstrual period least one year &gt; 52 year old ) exempt requirement . Medically acceptable form birth control include oral contraceptive , injectable implantable method , intrauterine device , tubal ligation ( perform 1 year screening ) , properly use barrier contraception . Additionally , use condom suggest adjunct method previously address protect sexually transmit disease provide additional protection accidental pregnancy . Sexually active men must agree use medically acceptable form contraception study continue 4 week last dose study drug . Able store patient kit/cooler contain drug refrigerator home . Patient exclude follow prior medication currently use use within designated time interval screen visit : 1 . Any B cell antibody deplete therapy , include plasmaphoresis Prosorba column ( 6 month ) 2 . Leflunomide , Adalimumab ( Humira ) ( 3 month ) 3 . Investigational biologics ( 2 month ) 4 . Infliximab ( Remicade ) ( 2 month ) 5 . Cyclosporine , sulphasalazine , auranofin , intramuscular gold , azathioprine , Dpenicillamine , tacrolimus ( 6 week ) 6 . Investigational small molecule ( e.g . NSAIDS Cox2 inhibitor ) ( 4 week ) 7 . Use 10mg/day prednisone equivalent ( 4 week ) 8 . Bolus intramuscular/intravenous ( IM/IV ) treatment corticosteroid ( &gt; 20 mg prednisone equivalent ) ( 4 week ) 9 . Intraarticular corticosteroid injection ( 4 week ) 10 . Etanercept ( Enbrel ) ( 4 week ) 11 . Anakinra ( Kineret ) ( 2 week ) 12 . Use one NSAID ( current ) 13 . Dose NSAID great maximum recommend dose product information ( current ) Significant concurrent medical disease include : 1 . Cancer , history cancer ( successfully resect cutaneous basal squamous cell carcinoma ) within 5 year screen visit . 2 . Any condition participation study judge physician detrimental patient , history significant unstable cardiac , pulmonary , gastrointestinal , neurological , psychiatric disease , DMARDrelated severe , potentially life threaten AE . 3 . Significant ongoing infection require systemic antibiotic , antifungal , antiviral , antimyobacterial therapy . Autoimmune connective tissue disorder rheumatoid arthritis ( e.g . Systemic Lupus Erythematosis , Scleroderma , Psoriatic Arthritis ) Grade 2 leukopenia ( i.e . white blood cell &lt; 3000/mm^3 [ SI unit : &lt; 3.0 x 10^9/L ) Thrombocytopenia thrombocytosis ( platelet &gt; 125,000/mm^3 &gt; 1,000,000/mm^3 [ SI unit : &lt; 125 x 10^9/L &gt; 1,000 x 10^9/L ] ) , respectively . Grade 2 liver function abnormality ( i.e . total bilirubin .1.5 x upper limit normal ; aspartate aminotransfersate [ AST/SGOT ] alanine aminotransferase [ ALT/SGPT ] &gt; 2.5 x upper limit normal . Renal disease ( include serum creatinine level &gt; 1.5 x upper limit normal ) . Any history immunodeficiency syndromes infection human immunodeficiency virus ( HIV ) , history hepatitis C chronic hepatitis B . Pregnant breastfeed woman woman plan become pregnant study within 4 week last dose study drug . Any major surgery , include joint surgery , within 3 month screen visit . Scheduled elective surgery study participation . Participated previous clinical trial use MM093 prior exposure MM093 . History severe hypersensitivity goat , sheep , cow milk . ( Patients lactose intolerant exclude ) . Any condition investigator feel would jeopardize integrity study ( e.g . CTCAE grade 2 clinical find laboratory result ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>